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Key messages
What is already known about this subject?
 ► The treatment of a septic arthritis requires a 
combination of at least one lavage/debridement 
and a long-lasting antibiotic administration.
 ► Usually, this initial antibiotic administration is 
parenteral during the first 2 weeks.
What does this study add?
 ► According to our randomised controlled trial, 
and at least for hand and wrist septic arthritis, 
total postsurgical antibiotic therapy can be 
limited to 2 weeks.
 ► Likewise, the initially systemic (and often 
empirical) parenteral antibiotic therapy can be 
switched to targeted oral medication after few 
days (1–2 days parenterally only).
How might this impact on clinical practice or 
future developments?
 ► Future patients with septic (hand and wrist) 
arthritis and a good evolution after surgical 
drainage might profit from significantly less 
antibiotics.
 ► This might limit potential adverse events, costs 
and complications of (parenteral) antibiotic 
therapy.
AbsTrACT
Objective The optimal duration of postsurgical 
antibiotic therapy for adult native joint bacterial arthritis 
remains unknown.
Methods We conducted a prospective, unblinded, 
randomised, non-inferiority study comparing either 2 or 
4 weeks of antibiotic therapy after surgical drainage of 
native joint bacterial arthritis in adults. excluded were 
implant-related infections, episodes without surgical 
lavage and episodes with a follow-up of less than 2 
months.
results We enrolled 154 cases: 77 in the 4-week arm 
and 77 in the 2-week arm. Median length of intravenous 
antibiotic treatment was 1 and 2 days, respectively. The 
median number of surgical lavages was 1 in both arms. 
Recurrence of infection was noted in three patients 
(2%): 1 in the 2-week arm (99% cure rate) and 2 in the 
4-week arm (97% cure rate). There was no difference 
in the number of adverse events or sequelae between 
the study arms. Of the overall 154 arthritis cases, 99 
concerned the hand and wrist, for which an additional 
subgroup analysis was performed. in this per-protocol 
subanalysis, we noted three recurrences: one in the 
2-week arm (97 % cure); two in the 4-week arm (96 % 
cure) and witnessed sequelae in 50% in the 2-week arm 
versus 55% in the 4-week arm, of which five (13%) and 
six (13%) needed further interventions.
Conclusions after initial surgical lavage for septic 
arthritis, 2 weeks of targeted antibiotic therapy is not 
inferior to 4 weeks regarding cure rate, adverse events 
or sequelae and leads to a significantly shorter hospital 
stay, at least for hand and wrist arthritis.
Trial registration number nCT03615781.
InTrOduCTIOn
Native joint bacterial arthritis is frequent and 
usually associated with considerable morbidity, 
need for hospitalisation and substantial financial 
costs.1–3 While the need for surgical drainage of 
these infections has been well established,4 5 the 
ideal duration and route of administration of anti-
biotic therapy remains unknown. For almost 40 
years, the recommended total duration of post-
surgical systemic antibiotic therapy has been 3–6 
weeks, with most clinicians prescribing 4 weeks 
for adults.3 Unfortunately, this recommendation is 
based on expert opinion and individual experience, 
rather than on research studies. Furthermore, clini-
cians often treat bacterial arthritis at all anatomic 
sites in the same way, with no distinction between 
small and large joints.
In the current era of critical shortages of effective 
antibiotics, antimicrobial stewardship principles 
suggest that a shorter treatment duration and early 
switch to targeted oral agents could decrease anti-
biotic-related adverse events,1 3 6 costs and possibly 
emergence of antimicrobial resistance. Retrospec-
tive studies,2 reviews7 and our own retrospective 
data3 suggest that just 2 weeks of targeted systemic 
antibiotic therapy after surgical drainage may be 
sufficient, especially for hand joints. In an attempt 
to provide an evidence base for antibiotic treat-
ment for adult native joint arthritis,5 we undertook 
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a prospective, randomised trial to determine if a postsurgical 
antibiotic course of 2 weeks, together with an early switch to 
oral targeted systemic antibiotics,3–5 is non-inferior in inducing 
remission to the currently recommended 4 weeks.3
MeTHOds
We performed a single-centre (at Geneva University Hospitals), 
prospective, unmatched, unblinded, randomised, interventional 
study from 1 March 2015 to 10 March 2018, with database 
closure on 18 May 2018. Inclusion criteria among patients 
diagnosed with native joint bacterial arthritis were: age ≥18 
years; underwent at least one articular lavage (by arthrotomy or 
arthroscopy; with or without synovectomy); and treatment with 
systemic antibiotic therapy. Of note, we allowed the inclusion of 
episodes with previous antibiotic therapy during at maximum 48 
hours prior to the first lavage and episodes with concomitant crys-
talline disease. Patients with an abscess in surrounding soft tissue 
were equally allowed to participate, but only if the abscess could 
be excised or drained in toto. Exclusion criteria were: recurrent 
bacterial arthritis; non-bacterial arthritis; history of allergies to 
multiple antibiotics; receiving long-term antibiotic prophylaxis 
because of immune-suppression; presence of left-side endocar-
ditis; incomplete joint lavage or >4 surgical lavages; plan for 
repetitive arthrocentesis as a therapeutic approach5; concomi-
tant spondylodiscitis or osteomyelitis;8 plan for arthrodesis or 
amputation; foot arthritis in a patient with diabetes mellitus9; 
presence of necrotiing fasciitis; intravertebral arthritis8; patient 
with or planned for a Girdlestone procedure10 11; patient who 
underwent a bone marrow transplantation; undergoing active 
oncological chemotherapy; or presence of foreign material in 
close vicinity to the infected joint. We also excluded infections for 
which published literature recommends either an unusually long, 
or a short duration of antibiotic therapy, for example, infection 
with mycobacteria,12 actinomycetes, gonococci, meningococci, 
fungi, brucellosis, mycoplasma or nocardia.13
We defined bacterial arthritis as the presence of: clinical find-
ings of joint infection (wound discharge, redness, warmth and 
new pain); and, at least two positive microbiological culture or 
Gram-strained smear14 or PCR of joint, pus or synovial tissues. 
Elevated serum inflammatory markers, positive histology of 
synovial tissue, elevated intra-articular white cell counts11 or 
abnormal radiological images were not required. We defined 
immune-suppression as the patient having undergone an organ 
transplantation, taking chronic corticosteroid medication 
equivalent to ≥15 mg prednisolone daily, requiring renal dial-
ysis, having diabetes mellitus, active cancer, liver cirrhosis of at 
least CHILD class C, severe chronic alcoholism, untreated HIV 
disease and agranulocytosis.
We defined sequelae as persisting non-infectious handicaps 
after adequate physiotherapy, ergotherapy (sensory-integrative 
therapy) and analgesia that was not pre-existent and attributed 
to the recent infection. We asked all patients to indicate their 
pain on a Likert scale, with responses ranging from 0 (least) to 
10 (greatest).
study conduct
We assigned eligible hospitalised patients, following a specified 
randomisation procedure (1:1, by computer-generated random 
numbers) to therapy with systemic antibiotic agents for either 
2 weeks (±3 days) or 4 weeks (±3 days). Treating surgeons, 
in consultation with an infectious diseases expert,15 selected 
the agents in the antibiotic regimen from a list of options we 
provided them. Initial therapy was empirical and was started 
after collecting intraoperative samples for culture. Treating clini-
cians could amend the antibiotic regimen (agent(s) or route of 
administration) according to the microbiological results and 
clinical evolution of infection. During the first days of therapy, 
the most frequently administered (empiric) antibiotic regimens 
were of the following given by intravenous route: co-amoxi-
clav; cefazolin; cefuroxime; cefepime; ertapenem; imipenem; 
piperacillin/tazobactam; vancomycin; or daptomycin. Defin-
itive therapy was based on of culture and sensitivity results, 
with a targeted oral antibiotic regimen selected from among 
the following agents: ciprofloxacin; levofloxacin; clindamycin; 
co-trimoxazole; doxycycline; linezolid; rifampicin; or fusidic 
acid. The timing for switching to oral therapy was at the discre-
tion of the treating clinicians and depended on the global evolu-
tion of the patient and the infection. The treating surgeons 
decided on: the arthrotomy or arthroscopy techniques; the 
timing of any emergency intervention4; whether to do synovec-
tomy; and when to repeat joint lavages. We avoided using intra-
synovial antibiotic infusions or irrigations with local antiseptics. 
Twelve months after enrollment of the last patient, we searched 
the hospital databases to determine if any of the enrolled patients 
had been seen in outpatient clinics for problems related to the 
operative site. Online supplementary appendix S1 shows the 
original protocol (in French).
Patient and public involvement
We involved all study participants on hospitalisation for surgical 
drainage of septic arthritis by asking them directly. We informed 
them orally in their native language and provided French-lan-
guage study documents. We moreover accompanied all patients 
until the test-of-cure visit, and beyond, if necessary. During 
accompaniment, the patients were always free to ask for addi-
tional information and clinical results. This was also the case 
for the study team that was free to ask to the patients. No infor-
mation was withheld. Although not a formal part of the study 
protocol, we think that the patients will help and promote the 
study idea in their respective communities. On a larger scale, 
the study team shall inform the public, that is, with interviews 
in the local press. In contrast, patients and public had not been 
involved in the design of the study. The study team had devel-
oped this prospective-randomised study according to their clin-
ical experience, academic interest, retrospective own data and 
on a scientific literature research. According to national ethical 
requirements, we will not provide a scientific copy of the final 
publication to every study participant, unless he or she wished to 
receive it specifically.
sample size considerations, outcome parameters and 
statistical analyses
The primary outcome for this study was the rates of remission 
of infection. Remission was defined as the complete absence 
of clinical, laboratory or radiological findings after a minimal 
follow-up of 2 months after treatment. Secondary endpoints 
were: remission in the subgroup of hand and wrist septic arthritis; 
the occurrence of adverse events related to antibiotic therapy; 
and the development of non-infectious sequelae of bacterial 
arthritis. Using a non-inferiority design, with an alpha level of 
5%, a power of 80%, expected remission rates of 96% in both 
study arms,2 3 we calculated that we needed 48 patients in each 
group to establish a non-inferiority margin of 10%. We planned 
interim analyses beginning after enrolment of the first 40 cases. 
Our intention-to-treat (ITT) population was composed of all 
randomised patients, while the per-protocol (PP) population 
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Figure 1 Study flow chart of patients. ITT, intention-to-treat.
included patients who completed the study without any major 
protocol deviation. Due to the predominance of hand arthritis 
cases, we performed a subgroup analysis for hand arthritis only, 
which included the fingers, hand and wrists. We compared treat-
ment groups using the Pearson χ2 or the Wilcoxon rank-sum test. 
Due to the small number of failures, we elected not to perform 
multivariate analyses. We used STATA software (V.9.0) and 
considered p values (two tailed) ≤0.05 as significant.
resulTs
Patients (entire study population; ITT analysis)
Among 211 native joint arthritis cases, 154 (analysis in 154 
different patients) were eligible for inclusion for the ITT anal-
yses. Overall, we excluded 34 of 211 patients and episodes 
due to various exclusion criteria, while the number of patients 
refusing to participate in the study was only 21 (21/211; 10%)
(see figure 1).
Clinically, these refusing patients and those excluded by inves-
tigators were a very heterogeneous group without clear anam-
nestic patterns or objectively common comorbidities (data not 
shown). Among the study patients, 77 were randomised to the 
4-week treatment arm and 77 to the 2-week treatment arm. 
Demographic characteristics were similar for the patients in the 
two groups (see table 1, left part).
The actual median duration of antibiotic therapy in the 
2-week arm was 14 days, and in the 4-week arm it was 28 days. 
Overall, 59 patients were women (38%), and the median age of 
all patients was 51 years. While many patients lacked comor-
bidities, 15 (10%) were chronically immune-compromised (due 
to diabetes mellitus (n=13), advanced cirrhosis (n=2), active 
cancer (n=3), solid organ transplant (n=1), steroid medication 
(n=2) or a combination of immune-suppressive conditions. 
In addition, six patients had an active psychiatric comorbidity 
and nine illicitly used drugs. The median American Society of 
Anesthesiologists’ Score16 for all enrolled patients was 2 points 
(IQR: 2–2 points).
Infections
The origin of infection varied greatly, including: surgical site 
infections17 (n=12); cat bites (n=16); cat scratches (n=2); 
dog bites (n=14); rat bite (n=1); human bites (n=3); infec-
tion of gouty tophus (n=1); intravenous drug abuse (n=9); 
direct trauma (n=48)18; and Baker cyst rupture (n=1). In 47 
cases, the origin was unknown. Bacteraemia was documented 
in six episodes (4%). There were no apparent seasonality19 or 
outbreak situations. On admission, the overall median serum C 
reactive protein level was 30 mg/L and the median pain score 
5 points (out of 10). The joints infected were: finger (n=95); 
wrist (n=3); knee (n=14); shoulder (n=7); ankle (n=3); elbow 
(n=1); hip (n=1); metatarsal (n=28); combination of wrist 
and ankle (n=1); and another combination of ankle and elbow 
(n=1). In 16 of the 154 episodes (10%), the infected joints had 
a prior known pathology: osteoarthritis (arthrosis) (n=6), cyst 
(n=2), rheumatological inflammation (n=4), psoriasis (n=1), 
meniscal lesion (n=1), recurrent subluxation (n=1) and chronic 
rotator calf injury (n=1). The infected joints also harboured 
intraarticular crystals in six cases (4%)11: calcium pyrophosphate 
in four, calcium apatite in one and urate in one. The median 
preoperative intracellular leucocyte count was 41 200 cells/
mm3, and the percentage of polynuclear leukocytes was 95%.11 
Culture results of intraoperative specimens revealed 31 different 
microbiological patterns. Staphylococcus aureus was the most 
commonly isolated pathogen, found in 48 episodes (31%); none 
of the strains was a methicillin-resistant strain. Streptococci were 
involved in 22 cases,20 Gram-negative pathogens in 35 episodes 
(including 19 due to Pasteurella spp,18 and skin commensals 
(coagulase-negative staphylococci, micrococci, corynebacteria 
or cutibacteria) in seven cases and the rest consisted of other 
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Table 1 Characteristics of patients treated with 2 weeks versus 4 weeks of systemic antibiotic therapy after surgical drainage of native joint 
septic arthritis (all arthritis cases on the left vs hand and wrist arthritis only on the right; both populations are intention-to-treat)
All arthritis cases
n=154
duration of antibiotic therapy 
Only hand arthritis cases
n=99
duration of antibiotic therapy
4 weeks
n=77
2 weeks
n=77
P
value *
4 weeks
n=44
2 weeks
n=55
P
value *
Female sex 31 (40%) 28 (36%) 0.62 Female sex 17 (35%) 20 (42%) 0.82
Median age 52 years 48 years 0.23 Median age 50 years 45 years 0.49
Immune-suppression† 7 (9%) 8 (10%) 0.79 Immune suppression† 4 (9%) 5 (9%) 1.0
Bacteraemia 2 (3%) 4 (6%) 0.37 Bacteraemia 0 (0%) 0 (0%) –
Median ASA Score16 2 (IQR: 1–2) 2 (IQR: 1–2) 0.13 Median ASA Score16 2 (IQR: 1–2) 2 (IQR: 1–2) 0.05
Pain score on admission (median) five points five points 0.33 Pain score on admission 
(median)
five points five points 0.31
Antibiotics before first surgery 21 (27%) 21 (27%) 0.95 Antibiotics before first surgery 12 (28%) 15 (29%) 0.92
Duration of presurgical antibiotics 
(median)
0 day 0 day 0.90 Duration of presurgical 
antibiotics (median)
0 day 0 day 0.49
Staphylococcus aureus 23 (30%) 25 (32%) 0.73 Staphylococcus aureus 
infection
11 (25%) 18 (33%) 0.40
Streptococci 19 (25%) 12 (16%) 0.16 Streptococci 12 (27%) 8 (16%) 0.12
Gram negative(s) 19 (25%) 16 (21%) 0.56 Gram-negative pathogens 15 (34%) 14 (25%) 0.35
Number of surgical lavages (median) 1 (IQR: 1–3) 1 (IQR: 1–3) 0.13 Number of surgical lavages 
(median)
1 (IQR: 1–3) 1 (IQR: 1–3) 0.11
Duration of intravenous therapy 
(median)
2 days 1 day 0.01 Duration of intravenous 
therapy (median)
2 days 1 day 0.02
Complete microbiological remission 75 (97%) 76 (99%) 0.56 Complete microbiological 
remission
42 (95%) 53 (96%) 0.82
Duration of sick leave (median) 36 days 28 days 0.31 Duration of sick leave 
(median)
36 days 27 days 0.29
Number of outpatient attendances 
(median)
6 controls 7 controls 0.05 Number of outpatient 
attendances (median)
7 controls 7 controls 0.70
Length of hospital stay (median) 6 days 4 days 0.01 Length of hospital stay 
(median)
4 days 3 days 0.01
Mechanical or neurological sequelae 33 (54%) 27 (47%) 0.47 Mechanical or neurological 
sequelae
21 (53%) 23 (48%) 0.67
Antibiotic-related adverse events 5 (6%) 2 (3%) 0.25 Antibiotic-related adverse 
events
2 (5%) 2 (4%) 0.82
*Pearson χ² test or Wilcoxon rank-sum tests, as appropriate.
†Immune-suppression=diabetes mellitus, active cancer, cirrhosis CHILD C, organ transplant and steroid medication equivalent to ≥15 mg prednisolone daily.
ASA, American Society of Anesthesiologists.
pathogens. Twenty-one infections were bimicrobial, and there 
were no polymicrobial cases.
Treatment
In all patients, we performed surgical drainage of the affected 
joint and administered systemic antibiotic therapy. Surgery was 
performed by open arthrotomy in all but seven cases (5%), 
which were drained by arthroscopy. table 1Enrolled patients 
were treated with 13 different initial parenteral regimens and 11 
different oral follow-on regimens. The most frequently admin-
istered parenteral antibiotics were co-amoxiclav (n=71), ceftri-
axone (n=3) and vancomycin (n=4). Overall, we administered 
parenteral β-lactam antibiotics in 107 (69%) cases. In three 
episodes, the entire antibiotic course was given intravenously, 
while in 32 cases treatment was with an oral agent from the start. 
The oral antibiotics prescribed were co-amoxiclav (74), quino-
lones (26), clindamycin (19), doxycycline (2), co-trimoxazole (3) 
or a combination of above. The table 2 resumes the antibiotic 
classes and administration forms, stratified on the study arm and 
key pathogen groups.
Overall, these allocations were balanced between both arms. 
We did not prescribe corticosteroids for the treatment of arthritis 
in any patient, but some were treated for pain with paracetamol, 
ibuprofen and opioids (in limited cases). The median number of 
surgical lavages was 1 in both groups. The overall median length 
of hospital stay was 4 days (IQR: 3-8 days), and it was longer in 
the short duration treatment arm (6 days vs 4 days; see table 1).
remission
Of the 154 episodes in the ITT population, 148 (96%) were 
microbiologically cured after an active median follow-up of 
0.5 years (IQR: 0.3–1.1 years) and a passive median follow-up 
of 2.2 years (IQR: 1.6–2.8 years). Among the six patients who 
ultimately failed on therapy, three patients (one in the 4-week 
arm, and two in the 2-week arm) finally revealed new patho-
gens completely different from the initial agents. We interpreted 
these episodes as novel episodes in terms of surgical site infec-
tions.17 Hence, the number of true microbiology-based recur-
rences was three (3/154; 2%) and these occurred after a median 
delay of 32 days after the end of treatment of the previous 
episode. There was no difference in the rate of microbiolog-
ical recurrences between the two treatment groups (see table 1); 
they occurred in 2 of 77 in the 4-week arm compared with 1 
of 77 in the 6-week arm (p=0.58). The three cases with micro-
biological recurrences involved one case caused by S. pyogenes, 
and two episodes caused by S. aureus. Formally, the 90% CIs 
(two tailed) regarding clinical remission were within the interval 
(between 0 and the 10% margin) and did not include the margin 
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Table 2 Main pathogen groups linked to corresponding selected antimicrobial substances and classes (overall ITT analysis)
n=154
Pathogen group
6 weeks
Parenteral antibiotics Oral antibiotics
4 weeks
Parenteral antibiotics Oral antibiotics
Staphylococcus aureus, n=48 Co-amoxiclav (n=14)
Clindamycin (n=1)
Cefuroxim (n=10)
Co-amoxiclav (n=17)
Clindamycin (n=5)
Levofloxacin (n=3)
Co-amoxiclav (n=13)
Cefazolin (n=2)
Cefuroxim (n=7)
Co-amoxiclav (n=17)
Clindamycin (n=5)
Levofloxacin (n=3)
Streptococci, n=31 Co-amoxiclav (n=11)
Penicillin (n=1)
Cefuroxim (n=6)
Co-amoxiclav (n=9)
Clindamycin (n=3)
Levofloxacin (n=3)
Co-amoxiclav (n=7)
Cephalosporins (n=3)
Cefuroxim (n=4)
Co-amoxiclav (n=5)
Clindamycin (n=3)
Levofloxacin (n=1)
Gram negatives, n=35 Co-amoxiclav (n=12)
Cephalosporins (n=6)
Quinolones (n=9)
Co-amoxiclav (n=10)
Co-amoxiclav (n=8)
Cephalosporins (n=8)
Quinolones (n=3)
Co-amoxiclav (n=12)
Pasteurella spp, n=17 Co-amoxiclav (n=6)
Cefuroxim (n=2)
Co-amoxiclav (n=7)
Levofloxacin (n=1)
Co-amoxiclav (n=6)
Cefuroxim (n=2)
Co-amoxiclav (n=8)
Levofloxacin (n=1)
Of note, the parenteral antibiotics are mostly empirical.
*Infections may be polymicrobial and thus the main antibiotics might be larger in spectrum than the main pathogens require.
(−0.7 percentage points (90% CIs −8.5% to +7.0%)). Idem 
for microbiological remissions (4.3 percentage points (90% CI 
−1.1% to +9.8%)).
Adverse events and complications
Overall, only eight patients (5%) reported adverse events that 
were attributed to antibiotic therapy: superficial fungal infection 
(n=3), allergic rash to amoxicillin or levofloxacin (n=3), severe 
diarrhoea due to co-amoxiclav (n=1) and dizziness due to clin-
damycin (n=1). As a consequence of adverse events, we changed 
the antibiotic or added fluconazole and probiotics in three cases. 
No patient developed Clostridium difficile-associated colitis and 
none left the study because of an adverse event. One patient devel-
oped a urinary tract infection, which we treated with another 
antibiotic agent inactive against the pathogen causing her bacte-
rial arthritis. The major non-antibiotic-related complications 
were: haematoma needing revision (n=3), hospital-acquired fall 
(n=2), new giant cell tumour (n=1), Raynauds’ phenomenon 
(n=1), stroke (n=1), scaphoid necrosis (n=1), influenza (n=1) 
and basilica vein thrombosis (n=1). The number of complica-
tions was similar in patients in the two study arms. Formally, the 
90% CI (two tailed) regarding adverse events also excluded the 
margin (3.8% percentage points (90% CI −1.7% to +9.5%)).
sequelae
Overall, in 60 episodes (39%), there were mechanical or neuro-
logical non-infectious sequelae, including: stiffness (n=16), 
flexion incapacity and adhesions (n=13; flexion contraction 
ranging between 5° and 30°), persistent pain (n=12), trigger 
zone (n=2), persistent dry wound (n=2), scaphoid necrosis 
(n=1), hypoesthesia (n=1) and Raynaud’s phenomenon (n=1). 
Many of these sequelae did not require any specific therapy, but 
a minority were severe enough to require corrective actions: 
tenolysis (n=4), surgical closure of persistent wound (n=1), 
immunological treatment (n=1), psychiatric follow-up (n=1), 
persistent vacuum-assisted suctions (n=1), prolonged senso-
ry-integrative therapy (n=1) or prolonged physiotherapy (n=4). 
Overall, 46 (of the 154) patients had follow-up radiographs and 
20 (43%) of these had evidence of ‘secondary osteoarthritis’ 
after a median delay of 2 months. The median duration of sick 
leave (officially granted by the treating physicians or surgeons to 
the affected patient) was 33 days. Of note, the 90% CI regarding 
the outcome substantial sequelae failed to fulfil the statistical 
non-inferiority requirements (6.7% percentage points (90% CI 
−8.6% to +22.1%)).
Hand and wrist arthritis (ITT analysis)
Among the 154 enrolled cases, 99 (64%) involved the hands or 
the wrist. Therefore, we decided to perform a subgroup analysis 
for these patients, of whom 44 were randomised to the 4-week 
arm and 55 to the 2-week arm. The actual median duration of 
postlavage antibiotic therapy was 14 days for the 2-week arm and 
28 days for the 4-week arm. The interphalangeal joints affected 
by bacterial arthritis were: thumb (n=15), index finger (n=29), 
middle finger (n=24), ring finger (n=7) and little finger (n=4). 
Metacarpal regions involved were: thumb (n=5), index finger 
(n=9), middle finger (n=1), ring finger (n=0) and little finger 
(n=1). In four cases, the wrist was involved. This subgroup’s 
patient characteristics (see table 1, right part) and outcomes 
were similar to those in the overall arthritis population. The 
most frequent oral antibiotic agents used for hand cases were 
co-amoxiclav, levofloxacin or clindamycin. The median number 
of surgical lavages was one. Microbiological recurrence was 
documented in three patients (4%): one in the 2=week arm and 
two in the 4-week arm (p=0.44). The proportion of sequelae 
and adverse events were equal between both arms in the hand 
arthritis group. However, the duration of intravenous therapy 
and the total length of hospital stay were shorter in the 2-week 
arm (see table 1).
PP analysis
Among the 99 episodes composing the ITT population of hand 
arthritis cases, we removed 17 (17/99; 17%), when constituting 
the PP population (see figure 1) because of unintended protocol 
violations or being lost to follow-up. There were no significant 
differences between patients in the two study arms in the PP 
population (see table 3 and figure 2).
The median age was 48 years; 32 (38%) were women, and 
9 were immune-suppressed, and the main cause of infection 
was bites (20 episodes). The predominant pathogens in these 
infections were S. aureus and Pasteurella multocida (20 and 12 
episodes, respectively). Overall, we treated 39 patients with a 
2-week course of antibiotics and 46 with a 4-week course, of 
which a median of 1 and 2 days was administered intravenously. 
In the two study arms, the median number of surgical lavages 
was 1 and the adverse events related to antibiotics were similar. 
We noted recurrence of bacterial arthritis after stopping anti-
biotic treatment in the same three patients as in the ITT popu-
lation (4%): 1 in the 2-week arm (98% remission) and 2o in 
the 4-week arm (95%; p=0.46). Various sequelae occurred in 
50% of the subjects in the 2-week treatment arm compared 
with 55% in the 4-week treatment arm. Only five (13%) and 
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Table 3 Characteristics of patients treated with 2 versus 4 weeks 
of systemic antibiotic therapy after surgical drainage of native joint 
bacterial arthritis of the hand and the wrist (per-protocol population 
only)
Hand arthritis (per-protocol 
analysis)
n=85
4 weeks
n=39
2 weeks
n=46 P value* 
Female sex 14 (36%) 18 (39%) 0.76
Median age 52 years 46 years 0.33
Immune-suppression† 4 (10%) 5 (11%) 0.93
Median ASA Score16 2 (IQR: 1–2) 2 (IQR: 1–2) 0.05
Serum C reactive protein at 
admission (median)
15 mg/L 8 mg/L 0.45
Pain score on admission (median) 4 points 5 points 0.15
Antibiotics before first surgery 10 (26%) 14 (30%) 0.63
Delay onset of infection surgery 
(median)
2 days (IQR: 1–3) 1 day (IQR: 0–2) 0.10
Staphylococcus aureus infection 10 (26%) 16 (35%) 0.36
Streptococci 9 (23%) 7 (15%) 0.36
Gram-negative pathogens 12 (31%) 13 (28%) 0.80
Number of surgical lavages 
(median)
1 (IQR: 1–1) 1 (IQR: 1–1) 0.23
Treatment with β-lactam 
antibiotics
28 (72%) 25 (76%) 0.65
Duration of intravenous therapy 
(median)
2 days 1 day 0.01
Complete microbiological 
remission
37 (95%) 45 (98%) 0.46
Duration of sick leave (median) 36 days 27 days 0.33
Number of outpatient attendances 
(median)
7 controls 8 controls 0.77
Length of hospital stay (median) 4 days 3 days 0.01
Mechanical or neurologic sequelae 21 (55%) 23 (50%) 0.52
Antibiotic-related adverse events 2 (5%) 2 (4%) 0.87
*Pearson χ² test or Wilcoxon rank-sum tests, as appropriate.
†Immune-suppression=diabetes mellitus, active cancer, cirrhosis CHILD C, organ 
transplant and chronic steroid medication.
Figure 2 Outcomes of arthritis therapy of the hands and wrists (subgroup analysis). X-axis: study outcome parameters. Y-axis: number of 
corresponding episodes with proportions and absolute number of cases.
six (13%) sequelae, respectively, required further and specific 
interventions (p=0.43). Statistically, our results equally fulfilled 
the non-inferiority requirements regarding the 10% margin for 
clinical (two tailed −0.8% percentage points (90% CI −8.5% to 
+7.0%)) and microbiological remission (4.3% (90% CI −1.1% 
to +9.8%)), as well as adverse events (0.8% (90%CI −7.0% to 
+8.5%)); but not regarding substantial sequelae (5.2% (90%CI 
−13.1% to +23.4%)).
dIsCussIOn
In this randomised trial with 154 adult cases of native joint 
bacterial arthritis, we found no significant difference in rates 
of clinical remission, adverse events or sequelae in patients 
treated with 2, compared with 4, weeks of antibiotic therapy 
after surgical drainage. Moreover, we found no differences in 
these two arms in analyses of both the ITT and the PP popula-
tions, as well as the subgroup of hand arthritis compared with 
cases in other anatomical sites in group comparisons. Statistically 
speaking, our study population fulfilled the formal non-inferi-
ority requirements regarding the outcome ‘remission’ (primary 
outcome). This was valid for both the ITT and PP analyses, the 
whole arthritis population and equally separated for the hand 
arthritis group only. Regarding the secondary outcomes ‘adverse 
events’ and ‘sequelae’, these statistical requirements were only 
fulfilled for adverse events in all analyses, whereas for substantial 
sequelae, for example, those with the need for further interven-
tions, our sample size was formally too small. The only excep-
tions to the similarity in the two treatment arms is that patients 
in the 4-week arm had a significantly longer length of hospital 
stay and received a longer duration of parenteral antimicro-
bial therapy. Only 10% of potentially eligible patients refused 
to participate in the study, which equally good participation. 
Moreover, clinically and anamnestically, the refusing patients 
and those excluded by investigators were a very heterogeneous 
group without clear patterns of objective common co-morbidi-
ties, avoiding an overt refusal bias.
In our review of the literature, we found no randomised clin-
ical trials in adult patients regarding the duration of postsurgical 
antibiotic therapy in patients with septic arthritis. Various expert 
groups have recommended different regimens for these cases, 
such as 2 weeks intravenous therapy for streptococci, 3–4 weeks 
intravenous for staphylococci and Gram-negative bacteria21 22 
and >4 weeks for immune-suppressed patients or those with 
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abnormal joints.21 Others have recommended parenteral treat-
ment for 2 weeks followed by another 2 weeks of oral treat-
ment,23 or just for a total 4 weeks.24 Some surgeons prescribe 
antibiotics for even longer periods without further justification.25 
In the paediatric orthopaedic literature, recommendations are 
often for a total antibiotic duration of just 2–3 weeks26–29 or 
even 10 days.30 The only investigation of hand bacterial arthritis 
in the adult population we found was a retrospective study by 
Meier et al2 that found good outcomes with no more than two 
surgical interventions and a median antibiotic duration of 14 
days in 79% of episodes, similar to what we found in our study.
The results of our trial also support our long-standing policy 
of providing only a short duration of initial parenteral antibiotic 
therapy for bacterial arthritis.3 This contrasts with widespread 
suggestions for several weeks of parenteral therapy for adult 
septic arthritis.21 22 We have found no evidence supporting the 
need for intravenous antibiotic administration for intrasynovial 
infections, especially for cases involving smaller joints, such as 
hand arthritis, that can be drained in toto without missed reser-
voirs of infection. Even in cases of bone infection, administra-
tion of highly bioavailable oral antibiotics can provide acceptable 
penetration levels,25 and paediatric arthritis data suggest that an 
early switch to oral antibiotics is as effective as prolonged paren-
teral regimens.26–30 In the aforementioned Meier study of 101 
cases of hand arthritis in adults, the transition from the paren-
teral to oral route occurred 3–5 days after definite surgery in the 
vast majority of the cases.2 Finally, very recently, colleagues from 
Oxford published a large multicentre prospective randomised 
study with various types of osteoarticular infections, mostly 
prosthetic joint infections. They could demonstrate the non-in-
feriority of an early switch to oral targeted medication after 7 
days postoperatively.31 In our study, we switched much earlier 
after 1–2 days. The lack of prospective randomised trials had 
made it difficult to change the view of experts’ that an initial 
2 weeks of parenteral antibiotic therapy is required for all 
moderate to severe orthopaedic infections. We hope that these 
recent prospective data, including ours, may make a start in 
revising that view, at least with hand bacterial arthritis.
Our study has limitations. The majority of arthritis cases 
involved the hand and wrist (n=99), with only 55 affecting larger 
joints. While the overall study population entirely fulfilled the 
sample size requirements for a non-inferiority trial, the subgroup 
of these 55 patients with larger joint infections did not, making 
the study underpowered for conclusions regarding non-hand 
episodes. With this issue in mind, we performed a second interim 
analysis and considered it unethical to continue the trial just to 
ensure sufficient numbers (≥250 cases in each study arm) for 
all subsets of joint infections. Another limitation is that we only 
compared treatment durations of 2 weeks versus 4 weeks, so 
we cannot comment on the possible value of shorter (or longer) 
durations of therapy. While there appears to be little benefit for 
treating native joint infections with longer than 4 weeks, there 
are almost no data favouring antibiotic courses shorter than 2 
weeks. The third limitation is that the study is performed in a 
single centre and that it was unblended, demanding for further 
confirmations in other settings, for example, regarding surgical 
techniques and approaches.
COnClusIOn
In adult patients who have undergone drainage of native joint 
bacterial arthritis, we found no difference in rates of clinical 
remission, adverse events or postinfectious sequelae for those 
treated with only 2 weeks, compared with 4 weeks’ of antibiotic 
therapy. Our data have statistical validity for hand arthritis cases 
but are underpowered for other anatomic localisations. As there 
are many clinical and economic advantages, and apparently no 
disadvantages, to shorter courses of antibiotic therapy, patients 
with hand bacterial arthritis might benefit from shorter treat-
ment courses. Similarly, our data support an earlier switch from 
parenteral to oral antibiotic therapy for these patients, which 
could help reduce financial costs, length of hospital stay and 
potentially intravenous line-related complications.
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